Pricing a hurdle for next | 合法醫療器材資訊網

2019年4月5日—Drugpricingisnotanewissue,butithasonlybecomemorevisiblewith...B-​TemiaissellingKeeogoinmarketsthattreatitasaclass1device, ...

Drug pricing is not a new issue, but it has only become more visible with the rise of new—and very expensive—treatments that could become one-time cures for diseases once considered incurable or that have historically needed chronic or lifelong treatment.

Consider the sticker prices for Kymriah and Yescarta, the first two CAR-T treatments to get FDA approval; they go for $475,000 and $373,000, respectively. Gene therapies are facing a similar challenge, with the companies developing them banking on a shift in thinking about how the healthcare industry approaches disease.

“These are one-time treatments that hopefully have curative effects and that’s exactly what all of us in society should want,” Sarepta Therapeutics CEO Doug Ingram told[1] FierceBiotech last summer. “The interesting thing is, the healthcare system is going to have to evolve and embrace these things.”

On...